FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087781368> ?p ?o ?g. }

• W3087781368 endingPage "870" @default.
• W3087781368 startingPage "857" @default.
• W3087781368 abstract "Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16‐week, randomized, placebo‐controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)‐4/IL‐13 signalling, significantly improved signs and symptoms with acceptable safety; longer‐term safety and efficacy data are lacking. To report the pharmacokinetic profile and long‐term safety and efficacy of dupilumab in children (aged ≥ 6 to < 12 years) with severe AD. Children (aged ≥ 6 to < 12 years) with severe AD were enrolled in a global, multicentre, phase IIa, open‐label, ascending‐dose, sequential cohort study and subsequent open‐label extension (OLE) study. Patients received single‐dose dupilumab 2 or 4 mg kg−1 followed by 8‐week pharmacokinetic sampling, then 2 or 4 mg kg−1 weekly for 4 weeks (phase IIa), followed by the same weekly regimen (OLE). Primary endpoints were dupilumab concentration–time profile and treatment‐emergent adverse events (TEAEs); secondary assessments included Eczema Area and Severity Index (EASI) and Peak Pruritus Numeric Rating Scale (PP‐NRS) score. Of 38 children enrolled, 37 completed phase IIa and 33 continued to the OLE. Nonlinear, target‐mediated pharmacokinetics characterized dupilumab concentrations (week 24–48 mean serum concentrations: 2 mg kg−1, 61–77 mg L−1; 4 mg kg−1, 143–181 mg L−1). TEAEs were mostly mild to moderate and transient; none led to treatment discontinuation. The most commonly reported TEAEs were nasopharyngitis (2 mg kg−1, 47%; 4 mg kg−1, 56%) and AD exacerbation (29% and 13%, respectively). Single‐dose dupilumab rapidly improved AD with further improvements through week 52. Mean EASI and PP‐NRS improved by −37%/−33% and −17%/−20% at week 2 (phase IIa) and −92%/−84% and −70%/−58% at week 52 (OLE), respectively. These safety and efficacy results support the use of dupilumab as a continuous long‐term treatment for children aged ≥ 6 to < 12 years with severe AD." @default.
• W3087781368 created "2020-10-01" @default.
• W3087781368 creator A5003155363 @default.
• W3087781368 creator A5003254447 @default.
• W3087781368 creator A5022161220 @default.
• W3087781368 creator A5022343550 @default.
• W3087781368 creator A5026963044 @default.
• W3087781368 creator A5029411965 @default.
• W3087781368 creator A5032223113 @default.
• W3087781368 creator A5033969727 @default.
• W3087781368 creator A5070477947 @default.
• W3087781368 creator A5071078845 @default.
• W3087781368 creator A5071907436 @default.
• W3087781368 creator A5077126049 @default.
• W3087781368 creator A5077395512 @default.
• W3087781368 creator A5085812346 @default.
• W3087781368 creator A5085831636 @default.
• W3087781368 date "2020-10-09" @default.
• W3087781368 modified "2023-10-18" @default.
• W3087781368 title "Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study" @default.
• W3087781368 cites W1497687130 @default.
• W3087781368 cites W189068515 @default.
• W3087781368 cites W198427113 @default.
• W3087781368 cites W2003620798 @default.
• W3087781368 cites W2011458820 @default.
• W3087781368 cites W2026147138 @default.
• W3087781368 cites W2037884221 @default.
• W3087781368 cites W2093616641 @default.
• W3087781368 cites W2101401558 @default.
• W3087781368 cites W2105521580 @default.
• W3087781368 cites W2306524933 @default.
• W3087781368 cites W2411361269 @default.
• W3087781368 cites W2524051065 @default.
• W3087781368 cites W2545263130 @default.
• W3087781368 cites W2555680885 @default.
• W3087781368 cites W2610814011 @default.
• W3087781368 cites W2751469248 @default.
• W3087781368 cites W2771011851 @default.
• W3087781368 cites W2802144480 @default.
• W3087781368 cites W2804177284 @default.
• W3087781368 cites W2944522746 @default.
• W3087781368 cites W2979884851 @default.
• W3087781368 cites W2988092601 @default.
• W3087781368 cites W3036352764 @default.
• W3087781368 cites W3036639957 @default.
• W3087781368 cites W3106710293 @default.
• W3087781368 cites W4211044813 @default.
• W3087781368 doi "https://doi.org/10.1111/bjd.19460" @default.
• W3087781368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8247037" @default.
• W3087781368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32969489" @default.
• W3087781368 hasPublicationYear "2020" @default.
• W3087781368 type Work @default.
• W3087781368 sameAs 3087781368 @default.
• W3087781368 citedByCount "33" @default.
• W3087781368 countsByYear W30877813682020 @default.
• W3087781368 countsByYear W30877813682021 @default.
• W3087781368 countsByYear W30877813682022 @default.
• W3087781368 countsByYear W30877813682023 @default.
• W3087781368 crossrefType "journal-article" @default.
• W3087781368 hasAuthorship W3087781368A5003155363 @default.
• W3087781368 hasAuthorship W3087781368A5003254447 @default.
• W3087781368 hasAuthorship W3087781368A5022161220 @default.
• W3087781368 hasAuthorship W3087781368A5022343550 @default.
• W3087781368 hasAuthorship W3087781368A5026963044 @default.
• W3087781368 hasAuthorship W3087781368A5029411965 @default.
• W3087781368 hasAuthorship W3087781368A5032223113 @default.
• W3087781368 hasAuthorship W3087781368A5033969727 @default.
• W3087781368 hasAuthorship W3087781368A5070477947 @default.
• W3087781368 hasAuthorship W3087781368A5071078845 @default.
• W3087781368 hasAuthorship W3087781368A5071907436 @default.
• W3087781368 hasAuthorship W3087781368A5077126049 @default.
• W3087781368 hasAuthorship W3087781368A5077395512 @default.
• W3087781368 hasAuthorship W3087781368A5085812346 @default.
• W3087781368 hasAuthorship W3087781368A5085831636 @default.
• W3087781368 hasBestOaLocation W30877813681 @default.
• W3087781368 hasConcept C126322002 @default.
• W3087781368 hasConcept C142724271 @default.
• W3087781368 hasConcept C16005928 @default.
• W3087781368 hasConcept C168563851 @default.
• W3087781368 hasConcept C197934379 @default.
• W3087781368 hasConcept C203092338 @default.
• W3087781368 hasConcept C204787440 @default.
• W3087781368 hasConcept C27081682 @default.
• W3087781368 hasConcept C2777014857 @default.
• W3087781368 hasConcept C2778329239 @default.
• W3087781368 hasConcept C2778715236 @default.
• W3087781368 hasConcept C2779824493 @default.
• W3087781368 hasConcept C2780699399 @default.
• W3087781368 hasConcept C2781413609 @default.
• W3087781368 hasConcept C71924100 @default.
• W3087781368 hasConcept C90924648 @default.
• W3087781368 hasConceptScore W3087781368C126322002 @default.
• W3087781368 hasConceptScore W3087781368C142724271 @default.
• W3087781368 hasConceptScore W3087781368C16005928 @default.
• W3087781368 hasConceptScore W3087781368C168563851 @default.
• W3087781368 hasConceptScore W3087781368C197934379 @default.
• W3087781368 hasConceptScore W3087781368C203092338 @default.
• W3087781368 hasConceptScore W3087781368C204787440 @default.

• next